Dicerna Pharmaceuticals Inc (DRNA) saw its loss narrow to $14.18 million, or $0.68 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $16.94 million, or $0.82 a share.

Revenues for the quarter were $0.16 million. The company has not recorded any revenues for the previous year period.

Operating loss for the quarter was $14.24 million, compared with an operating loss of $17 million in the previous year period.

"This quarter, we made the strategic decision to focus our resources on advancing our GalXCTM subcutaneous RNAi technology platform and to prioritize the product candidates emerging from this powerful product engine," said Douglas Fambrough, Ph.D., president and chief executive officer of Dicerna. "Our decision was based on the strength of the GalXC preclinical data and broad opportunities this technology enables in our core therapeutic areas of rare disease, chronic liver diseases, cardiovascular diseases and liver infectious diseases. In preclinical models across these areas, the potency and duration of action results for the GalXC platform have consistently supported the potential for target gene silencing in the liver with a simple, infrequent, subcutaneous injection paradigm."